Extraintestinal pathogenic <i>Escherichia coli</i> are associated with intestinal inflammation in patients with ulcerative colitis by Mirsepasi-Lauridsen, Hengameh C. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Extraintestinal pathogenic Escherichia coli are associated with intestinal inflammation
in patients with ulcerative colitis
Mirsepasi-Lauridsen, Hengameh C.; Halkjaer, Sofie Ingdam; Mortensen, Esben Munk;
Lydolph, Magnus C.; Nordgaard-Lassen, Inge; Krogfelt, Karen Angeliki; Petersen, Andreas
Munk
Published in:
Scientific Reports
DOI:
10.1038/srep31152
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Mirsepasi-Lauridsen, H. C., Halkjaer, S. I., Mortensen, E. M., Lydolph, M. C., Nordgaard-Lassen, I., Krogfelt, K.
A., & Petersen, A. M. (2016). Extraintestinal pathogenic Escherichia coli are associated with intestinal
inflammation in patients with ulcerative colitis. Scientific Reports, 6, [31152]. https://doi.org/10.1038/srep31152
Download date: 03. Feb. 2020
1Scientific RepoRts | 6:31152 | DOI: 10.1038/srep31152
www.nature.com/scientificreports
Extraintestinal pathogenic 
Escherichia coli are associated with 
intestinal inflammation in patients 
with ulcerative colitis
Hengameh C. Mirsepasi-Lauridsen1,2, Sofie Ingdam Halkjaer3, Esben Munk Mortensen3, 
Magnus C. Lydolph4, Inge Nordgaard-Lassen3, Karen Angeliki Krogfelt1 & 
Andreas Munk Petersen3,5
E. coli of the phylogenetic group B2 harbouring Extra intestinal Pathogenic Escherichia coli (ExPEC) 
genes are frequently seen as colonizers of the intestine in patients with active ulcerative colitis (UC). 
In this study, we describe the influence of E. coli Nissle (EcN) B2 as add-on treatment to conventional 
therapies in patients with active UC. For this study one hundred active UC patients were randomized 
to ciprofloxacin or placebo for 1 week followed by EcN or placebo for 7 weeks. Stool samples were 
collected at weeks 0, 1, 8, 12, where E. coli were characterized and fecal calprotectin was measured. We 
showed that in the active UC patient group receiving Placebo/EcN, fewer patients reached remission, 
in comparison to the patient group receiving Placebo/placebo (p < 0.05). Active UC patients initially 
colonized with E. coli B2 had increased fecal calprotectin values and Colitis Activity Index scores in 
comparison to patients colonized with E. coli A and D (p < 0.05*). In conclusion, treatment of UC 
patients with E. coli Nissle (B2) does not promote clinical remission and active UC patients colonized 
with E. coli B2 have an increased intestinal inflammation.
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon characterized by bloody diarrhoea and 
abdominal pain. UC is a multifactorial disease with flares that are probably triggered by changes in the intestinal 
microbiota followed by an abnormal immune response1.
The pathological findings associated with UC are an increase in certain inflammatory mediators, signs of oxi-
dative stress, a deranged colonic milieu, abnormal glycosaminoglycan (GAG) content of the mucosa, decreased 
oxidation of the short chain fatty acids (SCFAs), increased intestinal permeability, increased sulphide production 
and decreased methylation1. The dysbiosis in UC patients is defined by decreased levels of butyrate-producing 
bacteria followed by increase of expression of pro-inflammatory cytokines, contributing to the development of 
ulcerations in UC patients2. Increased prevalence of Enterobacteriaceae, especially Escherichia coli has been sus-
pected to play a role in the pathogenesis of UC3. Previous bacteriological analysis of colonic biopsies and fecal 
samples from patients with active UC showed an increased number of E. coli belonging to the B2 phylogenetic 
group harbouring extra-intestinal pathogenic Escherichia coli (ExPEC) genes3–5. Furthermore, E. coli B2 strains 
harbouring α -hemolysin caused increased intestinal permeability, and ExPEC isolated from UC patients had 
inflammation-inducing properties possibly linked to UC pathogenesis6,7.
Probiotics have been used to maintain remission in UC patients and it was shown that VSL #3 supplemen-
tation in active and inactive UC patients reduces rectal bleeding and disease activity8. E. coli strain Nissle 1917 
(EcN), belonging to the B2 phylogenetic group, was isolated from the feces of a German soldier, who seemed to 
be protected from infectious diarrhoeal disease9. Since then, many studies have been performed on the unique 
pattern of fitness, the expression of virulence factors in EcN and the use of this strain as a probiotic10,11. Genomic 
studies of EcN showed that, in contrast to other non-pathogenic strains, EcN expresses microcins and adhesins, 
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but lacks α -hemolysin12,13. EcN was reported to maintain remission in UC patients with active disease and to 
prevent colitis in different murine colitis models10,11,14–16. In the randomized double-blinded study of EcN given 
as add-on treatment to patients with active UC, we showed that significantly fewer patients treated with EcN 
reached symptomatic remission and that significantly more patients treated with EcN withdrew from the study17. 
Previous studies show that EcN is very closely linked to ExPEC isolates isolated from urinary tract infections, 
such as CFT073 and 536, even though certain virulence factors are not transcribed in EcN18–20. Fecal calpro-
tectin is a non-invasive marker of intestinal inflammation used to distinguish between functional and organic 
bowel diseases and to evaluate disease activity in UC patients21. Clinical colitis activity indices correlate signifi-
cantly with microscopic and macroscopic endoscopic scores, using clinical symptoms and laboratory findings22. 
However, fecal calprotectin predicts endoscopic disease activity far more reliably than the Colitis Activity Index 
(CAI) score23. In this study, the CAI score was performed as described by Rachmilewitz, including laboratory 
findings, CRP and hemoglobin24. Studies showed that UC patients between relapses have a calprotectin value 
between 123–213 mg/kg25. Therefore, in this follow-up study a calprotectin value of > 200 mg/kg was used as the 
criterion for active UC. Our aim was to evaluate the effects on intestinal inflammation of ciprofloxacin (Cipro) 
and orally administered EcN as add-on to conventional therapies in patients with active UC in correlation to fecal 
calprotectin values. Furthermore, the association between intestinal inflammation and primary colonization with 
E. coli B2 in active UC patients was assessed.
Results
Patient characteristics. One hundred patients with active UC, defined by a CAI score ≥ 6, were included 
in the study and randomized to four treatment groups: 1 week of ciprofloxacin or placebo followed by 7 weeks 
of EcN or placebo, with 25 patients in each group17 (Fig. 1). We designated the groups as Cipro/EcN (A), Cipro/
placebo (B), Placebo/EcN (C) and Placebo/placebo (D).
Baseline characteristics for fecal calprotectin values were analysed using the t-test (Two-tailed), where three 
groups (A, B, C) were compared to the Placebo/placebo group. We found no significant differences in the median 
values for fecal calprotectin between Placebo/placebo (D) and Placebo/EcN (C) and Cipro/EcN (A) at week 0. 
However, there was a difference in the median fecal calprotectin value between the Placebo/placebo (D) and 
Cipro/placebo (B) groups (p < 0.05) at week 0, with a higher median fecal calprotectin in the Cipro/placebo 
group. Yet this had absolutely no effect over time and at week 12 where the fecal calprotectin was low and patients 
from the Cipro/placebo group reached remission at the same rate as the Placebo/placebo group (Table 1 and 
Fig. 1).
The number (n) of UC patients with fecal calprotectin > 200 mg/kg (indicating a substantial inflammatory 
activity) in the four treatment groups (N = 25 individuals in each group) upon inclusion was: 17/25 patients in 
Cipro/EcN (A), 21/25 patients in Cipro/placebo (B), 17/25 patients in Placebo/EcN (C) and 18/25 patients in 
Placebo/placebo (D) treatment groups. Thus, these patients (with calprotectin > 200) are defined as having a 
confirmed inflammatory activity of UC.
Treatment with Escherichia coli Nissle 1917 (EcN) on active UC patients. Active UC patients 
with an initial fecal calprotectin level > 200 mg/kg were included. At follow-up 12 weeks after initiation of treat-
ment, 61% (11/18) of the patients in Placebo/placebo (D), 41% (7/17) of the patients in Cipro/EcN (A), and 57% 
(12/21) of the patients in Cipro/placebo (B) reached a fecal calprotectin value < 200 mg/kg. However, in the group 
Placebo/EcN, (C) only 18% (3/17) reached a fecal calprotectin value < 200 mg/kg (Fig. 2). Significantly fewer 
active UC patients treated with Placebo/EcN (C) reached remission compared to patients treated with Placebo/
placebo (D), p < 0.05 (Fig. 2).
When comparing groups receiving EcN (Cipro/EcN and Placebo/EcN; (A) & (C)) with groups not receiving 
EcN (Cipro/placebo and placebo/placebo; (B) & (D)), it was demonstrated that groups receiving EcN did not 
achieve remission (fecal calprotectin < 200 mg/kg) as often as groups not receiving EcN, i.e. 31% (10/34) for (AC) 
versus 59% (23/39) for (BD), p ≤ 0.05, Fig. 3.
Fecal calprotectin levels in patients treated with ciprofloxacin and/or EcN compared to placebo. 
Fecal calprotectin values from weeks 0, 1, 8, and 12 of all 100 UC patients (regardless of the calprotectin value of 
the initial stool sample) were evaluated using the Two-way ANOVA test. There were no significant differences 
in the distribution of fecal calprotectin values over time, when comparing the four treatment groups, Cipro/
EcN (A), Cipro/placebo (B), Placebo/EcN (C) and Placebo/placebo (D), p = 0.067 (Table 1). The table shows the 
number of fecal samples sent to the laboratory during the study, and the median fecal calprotectin values, by study 
groups. However, in order to see whether EcN has an overall effect, groups treated with EcN (AC) were compared 
to groups not treated with EcN (BD). When comparing the experimental groups receiving EcN from weeks 0, 1, 8, 
and 12 (Cipro/EcN and Placebo/EcN (AC)) with groups not receiving EcN (Cipro/placebo and Placebo/placebo 
(BD)), a non-significant trend of higher fecal calprotectin levels was found in patients treated with EcN, p = 0.053.
The effect of antibiotic treatment on intestinal inflammation measured by fecal calprotectin. 
Patients with an initial fecal calprotectin level > 200 are included. Of patients treated with antibiotics (Cipro/EcN 
and Cipro/placebo) as add-on treatment, 52% (19/38) reached a fecal calprotectin value < 200 mg/kg, thus under 
remission; and 40% (14/35) of patients who were not treated with antibiotics (Placebo/EcN (C) and Placebo/
placebo (D) reached a fecal calprotectin value < 200 mg/kg. This difference was, however, not significant (Fig. 4).
E. coli colonisation of UC patients during the different treatments. E. coli was isolated and char-
acterised phylogenetically from patients’ fecal samples during the study period. It was seen that patients were 
colonised by different E. coli strains simultaneously. Remarkably, the Placebo/EcN (C) exhibited higher diversity 
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in the E. coli phylogenetic groups colonising the intestine. This suggests that E. coli Nissle does not colonise the 
intestine by competitive exclusion of other E. coli (Table 2).
The effect of antibiotic treatment on E. coli B2 colonization. When evaluating the effect of anti-
biotics on E. coli B2 colonization, all 100 UC patients were included regardless of the fecal calprotectin concen-
tration in the initial stool sample. Patient group B (treated with ciprofloxacin only) was initially colonized with 
50% (12/24) E. coli B2 at week 0, prior to ciprofloxacin treatment. After antibiotic treatment, the number of the 
patients colonized with E. coli B2 was reduced to 5% (1/21), 37% (7/19) and 40% (6/15) at weeks 1, 8, and 12, 
respectively (Table 2). These results demonstrate that one week’s treatment with ciprofloxacin reduced the num-
ber of active UC patients colonized with E. coli B2 immediately after the treatment, but no long-term effect on E. 
coli B2 colonization could be demonstrated.
In group D (no antibiotics), 52% (13/25) of the patients were colonized with E. coli B2 at inclusion at week 0. 
In this group, the number of patients colonized with E. coli B2 were 42% (10/24), 45% (9/20) and 38% (6/16) at 
weeks 1, 8 and 12, respectively (Table 2). Note that some of the patients have been colonised with more than one 
E. coli strain with different E. coli phylogenetic groups (Table 2).
Colonization with E. coli B2 and intestinal inflammation in active UC patients at inclusion. UC 
patients initially colonized with E. coli B2 had significantly increased fecal calprotectin values at week 0 in com-
parison to UC patients colonized with E. coli of phylogenetic groups A and D p < 0.05 (Fig. 5). However, the 
Figure 1. Flowchart of patient inclusion and withdrawals and of number fecal samples sent to the 
laboratory. 
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differences were not significant when comparing fecal calprotectin values of patients initially colonized with 
E. coli B2 with patients colonized with E. coli B1, p > 0.05 (Fig. 5).
Likewise, significantly increased CAI scores were found at week 0 in patients colonized with E. coli B2 com-
pared to patients colonized with E. coli A and D, p < 0.05 (Fig. 6). The differences were not significant when 
comparing CAI scores of patients initially colonized with E. coli B2 with those of patients colonized with E. coli 
B1, p > 0.05.
Discussion
Ulcerative colitis patients are conventionally treated with anti-inflammatory medication. Since bacterial dysbiosis 
is suggested to cause disease relapses in UC, antibiotics and probiotics have also been used as treatment strate-
gies26–28. E. coli strain Nissle 1917 (EcN), of the B2 phylogenetic group has been reported to maintain remission 
in UC patients and prevent colitis in a mouse model10,11,14–16.
In the previous study17, it was shown that there was no benefit of using EcN as an add-on treatment to con-
ventional therapies for active UC. Activity was determined by the Colitis Activity Index (CAI) questionnaire. 
Clinical, laboratory and endoscopic evidence show high specificity and sensitivity using CAI scores29. The 
disadvantage of using the CAI score is that it is unknown whether or not a high score is caused by a UC flare, by 
irritable bowel syndrome-like symptoms or by adverse reactions to treatment regimes, e.g. ciprofloxacin or the 
Weeks 0 1 8 12
Cipro/EcN (A)
 *n/N 25/25 (100%) 24/25 (96%) 16/21 (76%) 14/19 (74%)
 Median fecal Calprotectin (mg/kg) 836 474 371 251
Cipro/placebo (B)
 *n/N 24/25 (96%) 21/25 (84%) 19/22 (86%) 15/21 (71%)
 Median fecal Calprotectin (mg/kg) 1503 534 201 181
Placebo/EcN (C)
 *n/N 25/25 (100%) 18/23 (78%) 14/16 (87%) 12/14 (86%)
 Median fecal Calprotectin (mg/kg) 519 737 378 184
Placebo/Placebo (D)
 *n/N 25/25 (100%) 24/25 (96%) 20/20 (100%) 16/20 (80%)
 Median fecal Calprotectin (mg/kg) 643 235 55 69
Table 1.  Overview of experimental groups (intention-to-treat analysis) included in the study per protocol 
during 12 weeks’ follow up (0, 1, 8, and 12). * n (number of received stool samples)/N (number of the patients 
remaining in the study). The table shows the number of fecal samples sent to laboratory during the study from 
each group and the median fecal calprotectin values.
Figure 2. Comparison of the UC patient groups reaching fecal calprotectin values <200 mg/kg. Percentage 
reaching remission (calprotectin values < 200 mg/kg) during 12 weeks follow-up (intention to treat-analysis) 
treated with Placebo/placebo (D), Cipro/EcN (A), Cipro/placebo (B) or Placebo/EcN (C) as add-on treatment.
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probiotic EcN. In the last decade, fecal calprotectin has been used as a surrogate marker for inflammation, as a 
predictor for relapses30–32, and as a marker for mucosal healing in IBD patients33,34. Since fecal calprotectin pre-
dicts endoscopic disease activity far more reliably than a CAI score22, we performed the present follow up study 
using calprotectin as the marker of intestinal inflammation. The potential beneficial use of EcN as a probiotic, 
maintaining remission in patients with UC, has previously been described10,11. In this extension of our previous 
study of add-on treatments with one week of ciprofloxacin and/or EcN for seven weeks compared to ciprofloxacin 
and/or placebo for seven weeks17, we demonstrate by the use of fecal calprotectin measurements that EcN was in 
fact not beneficial as add-on treatment given to patients with active UC.
Treatment with EcN resulted in fewer active UC patients reaching remission (fecal calprotectin < 200 mg/kg) 
in comparison to active UC patients not treated with EcN. Actual fecal calprotectin values from weeks 0, 1, 8 and 
12 between patients treated with EcN compared to patients not treated with EcN (including all patients as long as 
they participated in the study) show a non-significant trend of higher fecal calprotectin levels in patients treated 
with ECN, (p = 0.053) (Table 1). The explanation why this observation did not reach statistical significance might 
Figure 3. UC patients treated/not treated with EcN reaching fecal calprotectin values <200 mg/kg during 
12 weeks follow-up (intention to treat). 31% of the patients treated with EcN (AC) as add-on treatment 
reached a calprotectin value < 200 mg/kg, while 59% of the patients not treated with EcN (BD) reached a 
calprotectin value < 200 mg/kg, p < 0.05* .
Figure 4. UC patients treated/not treated with ciprofloxacin reaching fecal calprotectin values <200 mg/kg  
during 12 weeks follow-up (intention to treat). There are no significant differences in patient groups treated 
with ciprofloxacin (AB) as add-on treatment in comparison to patient groups not treated with ciprofloxacin (CD).
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be that more UC patients in the groups treated with EcN as add-on treatment withdrew from the study, making it 
impossible to follow up on the calprotectin levels among patients with the possibly worst outcome.
Based on fecal calprotectin results from weeks 0, 1, 8 and 12 of active UC patients with an initial fecal calpro-
tectin level > 200 mg/kg, no significant differences in active UC disease activity could be found between patients 
treated or not treated with ciprofloxacin. A meta-analysis performed on the efficacy of broad spectrum antibiotics 
Weeks 0 1 8 12
E. coli Phylogeny groups Cipro/EcN (A)
E. coli B2 (13/25) 52% (5/24) 21% (10/19) 53% (7/16) 44%
E. coli D (6/25) 24% (2/24) 8% (3/19) 16% (1/16) 6%
E. coli A (5/25) 20% (4/24) 17% (8/19) 42% (7/16) 44%
E. coli B1 (0/25) 0% (2/24) 8% (3/19) 16% (3/16) 19%
No growth (4/25) 16% (16/24) 67% (0/19) 0% (0/16) 0%
 Cipro/placebo (B)
E. coli B2 (12/24) 50% (1/21) 5% (7/19) 37% (6/15) 40%
E. coli D (3/24) 13% (2/21) 10% (3/19) 16% (3/15) 20%
E. coli A (6/24) 25% (1/21) 5% (8/19) 42% (3/15) 20%
E. coli B1 (1/24) 4% (0/21) 0% (3/19) 16% (5/15) 27%
No growth (4/24) 17% (17/21) 81% (1/19) 5% (0/15) 0%
 Placebo/EcN (C )
E. coli B2 (8/25) 32% (11/18) 61% (9/14) 64% (6/12) 50%
E. coli D (8 /25) 32% (7/18) 39% (4/14) 29% (4/12) 33%
E. coli A (7/25) 28% (2/18) 11% (1/14) 7% (3/12)33%
E. coli B1 (5/25) 20% (2/18) 11% (1/14) 7% (3/12) 28%
No growth (2/25) 8% (1/18) 6% (1/14) 7% (0/12) 0%
Placebo/placebo (D)
E. coli B2 (13/25) 52% (10/24) 42% (9/20) 45% (6/16) 38%
E. coli D (5/25) 20% (6/24) 25% (4/20) 20% (5/16) 31%
E. coli A (4/25) 16% (8/24) 33% (4/20) 20% (4/16) 25%
E. coli B1 (6/25) 24% (2/24) 8% (3/20) 15% (1/16) 6%
No growth (2/25) 8% (3/24) 13% (4/20) 20% (1/16) 6%
Table 2.  E. coli isolated during the study from patient groups. * n (No. of stool samples with E. coli X 
phylogeny)/N (No. of stool samples) in per cent. Percentage of E. coli B2, D, A, B1 phylogeny groups in each 
patient group during 12 weeks’ follow up.
Figure 5. Week 0 fecal calprotectin value in mg/kg in experimental groups (25 patients in each group) 
included in the study. One way ANOVA test was performed (mean, SEM), comparing differences between 
mean fecal calprotectin values of the patients colonized with E. coli B2 phylogenetic group versus E. coli A, D, 
B1. There is a significant difference between the fecal calprotectin mean values of the patient initially colonized 
with E. coli B2 in comparison to patients colonized with E. coli D and A, p < 0.05* . However, these differences 
were not significant between patients colonized with B1 E. coli versus B2 E. coli.
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in IBD patients showed 2.3 times better clinical improvement in patients receiving antibiotics such as ciproflox-
acin35,36. However, patients included in the ciprofloxacin treatment groups were only treated with ciprofloxacin 
for 7 days, while studies so far recommend up to 16 weeks of treatment36. A longer duration of treatment with 
ciprofloxacin might change the outcome and cause remission in UC patients. Additionally, 50% of the patients 
included in this study were treated with EcN, which might have a negative effect on the ciprofloxacin treatment 
outcome.
When comparing the ciprofloxacin treatment effect on E. coli B2 colonization in UC patients, there were no 
significant differences in the number of patients colonized with E. coli B2 either before treatment (week 0) or after 
week 12, even though a reduction in E. coli B2 colonization was found immediately after week 1 in patients treated 
with ciprofloxacin (Table 2). It has previously been shown in mice colonized with IBD associated E. coli that IBD 
associated E. coli reappeared some days after treatment with ciprofloxacin for 7 days37. This study indicates that 7 
days of treatment with ciprofloxacin is not efficient to eradicate IBD associated E. coli. However, more studies are 
needed to clarify the efficiency of antibiotics in order to eradicate IBD associated E. coli.
Recent bacteriological studies on IBD patients show a characteristic individual variability in the mucosal 
bacteria and a large number of E. coli species belonging to the B2 and D phylogenetic groups3,4. The present study 
shows that UC patients initially colonized with E. coli B2 had significantly increased fecal calprotectin values and 
CAI scores at week 0 compared to patients colonized with E. coli D and A. The phylogenetic group B2 comprises 
among others ExPEC strains38. Furthermore, it is shown by genome sequencing that EcN is very closely linked to 
ExPEC isolates causing urinary tract infections, such as CFT073 and 536, even though certain virulence factors 
are not transcribed in EcN19.
These results indicate that the UC-associated E. coli B2 are associated not only with active disease but also with 
an increased burden of inflammation in UC patients. We did not see any beneficial effect of neither ciprofloxacin 
nor EcN. Therefore, it is still possible that eradication of UC associated E. coli B2, using other constellations of 
antibiotics and/or probiotics might benefit UC patients with active disease. Future trials should, however, take the 
presence or absence of E. coli B2 into account when evaluating the effect of these treatments.
Materials and Methods
Study design and samples. One hundred consecutive patients with flares of UC without any known gas-
trointestinal infections and without use of antibiotics for the past 4 weeks were included in the study. Patients 
included were aged > 18 years, with a CAI score ≥ 639. The study was designed as a randomized double-blind 
placebo-controlled study of the effect of an add-on treatment of patients with flares of UC. Patients were allocated 
to one of four treatment groups: 1) Ciprofloxacin (500 mg twice daily) for one week followed by EcN (1 capsule 
twice daily) for 7 weeks; 2) Ciprofloxacin (500 mg twice daily) for one week followed by placebo for 7 weeks; 3) 
Placebo for one week followed by EcN (1 capsule twice daily) for 7 weeks; and 4) Placebo for one week followed by 
placebo for 7 weeks17. Standard medical care and therapies were allowed throughout the study, however, patients 
requiring treatment with systemic steroids or TNF-alfa inhibitors were excluded from the study, topical steroids 
were allowed. Standard medical treatments were comparable between groups as described in Petersen et al.17. 
Figure 6. CAI score in experimental groups (25 patients in each group) included in the study. One way 
ANOVA test was performed (mean, SEM), comparing differences between the mean CAI score of the patients 
colonized with E. coli B2 phylogenetic group versus E. coli A, D, B1. There is a significant difference between 
CAI scores in the patients initially colonized with B2 E. coli and the patients colonized with E. coli A and D, 
p < 0.05*. However, the differences were not significant when comparing the CAI scores of patients initially 
colonized with E. coli B2 with patients colonized with E. coli B1.
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Patients were randomized 1:1:1:1, allowing 25 patients to be included in each group. Fecal samples were collected 
at weeks 0, 1, 8 and 12. An overview of the study material and the samples taken is seen in Fig. 1.
Ethical Statement. Permission for treatment study and the recruitment of participants was approved by the 
Scientific Ethic Committee for Copenhagen Regional Hospitals (Permission no. H-1-2009-110). All participants 
gave their informed written consent. Collection of samples and data was carried out in accordance with the rele-
vant guidelines as previously described17.
Isolation of E coli from fecal samples. Fecal samples were sent for analysis at Statens Serum Institut, 
Copenhagen, Denmark. Laboratory staff analysed E. coli from the fecal samples without knowledge of the ran-
domisation in the placebo-controlled study. Ten μ g fresh stool sample were mixed in 2 ml phosphate buffered 
saline (PBS, pH 7.38) and 10 μ l were plated on SSI enteric medium agar plates (SSI, Hillerød, Denmark, product 
no. 724) and incubated overnight at 37 °C. Bacteria from the SSI enteric medium were harvested and plated on 
SSI blue agar plates (SSI, Hillerød, Denmark, product no. 694) selective for gram negative bacteria and incubated 
overnight at 37 °C. E. coli colonies were isolated from the SSI blue agar plate and tested for Beta-glucuronidase40 
((PGUA), SSI, Hillerød, Denmark, product no. 1033) and Indol (Biomérieux, Denmark, product no. 56541). 
Isolated E. coli were inoculated in Luria broth (LB) (Sigma-Aldrich, GmbH, Germany) and incubated overnight 
at 37 °C. Twenty-five μ l of bacterial culture in LB were diluted in 975 μ l of sterile water, boiled at 100 °C for 
15 min., centrifuged for 10 minutes at 14.000 × g, and the supernatant (bacterial DNA) was transferred to a new 
tube and stored at − 20 °C for PCR testing. E. coli isolates with different colony morphologies from the SSI blue 
agar plates were harvested, dissolved in 15% glycerol (Sigma-Aldrich, GmbH, Germany. Cat: 67757) in beef stock 
(SSI, Hillerød, Denmark, product no. 1056), and stored at − 80 °C.
E. coli phylogenetic group determination. E. coli phylogenetic groups (A, B1, B2 and D) were determined 
by a simple PCR procedure based on the genes chuA, yjaA and an anonymous DNA fragment, using primers and 
conditions exactly as described by Clermont et al.41.
Determination of fecal calprotectin. CALPROLABTM Calprotectin ELISA (ALP) (Calpro AS, Oslo, 
Norway) is an enzyme-linked immunoassay (ELISA) based on polyclonal antibodies to human calprotectin 
(S100A8/A9). According to the manufacturer’s instructions, 100 mg frozen fecal samples were homogenized in 
4.9 ml extraction buffer using fecal extraction tubes (Calpro AS, Product No. CAL0500). The supernatants were 
diluted in sample diluent solution (1:100) before testing. Fecal extracts with values above measuring range were 
further diluted and re-tested. Values > 50 mg/kg were regarded positive42,43.
Statistical analysis. Kaplan-Meier curves were used to compare groups. Test of equality of survival distributions 
for the different clinical treatment groups was performed using the Mantel-Cox (log-rank) test. The softwares 
“SAS 9.4” and “GraphPad Prism 5” were used for statistical analyses. The differences between the fecal calprotectin 
levels in the four patient groups among patients treated/not treated with EcN, were analysed using the SAS 
Two-way ANOVA test. The differences between fecal calprotectin levels at week 0 in patients colonized/not 
colonized with B2 E. coli were analysed using the t-test. A p < 0.05 is considered significant.
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